胆管癌干细胞标志的研究进展

doi:10.3969/j.issn.1004-616x.2017.05.017

摘要/Abstract

摘要： 胆管癌是胆道系最常见的恶性肿瘤，目前治疗方式以手术为主，术后辅助化疗，但这类患者具有预后差、复发率高且易转移的特点。肿瘤干细胞学说认为肿瘤组织中存在一类具有多向分化、无限增殖能力的干细胞。这类干细胞为我们寻找某种治疗和抑制肿瘤细胞生长和增殖的方法提供了切入点，而研究、分离及鉴别这类干细胞需要特殊标志，本文就胆管癌干细胞增殖、分化和转移过程中出现的标志予以综述。

关键词: 胆管癌, 肿瘤, 干细胞, 标志

中图分类号:

R735.8

王龙, 安慧蒙, 彭为, 王亚运, 张勇, 郑鹏飞, 程志斌. 胆管癌干细胞标志的研究进展[J]. 癌变·畸变·突变, 2017, 29(5): 402-405.

[1] ROMANO M,DE FRANCESCO F,GRINGERI E,et al. Tumor microenvironment versus cancer stem cells in cholangiocarcinoma:Synergistic effects?[J]. J Cell Physiol,2016,231(4):768-776.
[2] Reya T,Morrison S J,Clarke M F,et al. Stem cells,cancer,and cancer stem cells[J]. Nature,2011,414(6859):105-111.
[3] BAUTISTA W,PEREZ-ALVAREZ V,BURCZYNSKI F,et al. Membrane potential differences and GABAA receptor expression in hepatic tumor and non-tumor stem cells[J]. Can J Physiol Pharmacol,2014,92(1):85-91.
[4] JIAO X L,ZHAO C,NIU M,et al. Downregulation of CD24 inhibits invasive growth,facilitates apoptosis and enhances chemosensitivity in gastric cancer AGS cells[J]. Eur Rev Med Pharmacol Sci,2013,17(13):1709-1715.
[5] LEE T K,CASTILHO A,CHEUNG V C,et al. CD24(+) liver tumorinitiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation[J]. Cell Stem Cell,2011,9(1):50-63.
[6] KIM K,MIN HS,CHIE EK,et al. CD24 expression predicts distant metastasis in extrahepatic bile duct cancer[J]. World J Gastroenterol,2013,19(9):1438-1443.
[7] KEERATICHAMROEN S,LEELAWAT K,THONGTAWEE T,et al. Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival[J]. Int J Oncol,2011,39(4):873-881.
[8] LEE HJ,CHOE G,JHEON S,et al. CD24,a novel cancer biomarker,predicting disease-free survival of non-small cell lung carcinomas:are trospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification[J]. J Thorac Oncol,2010,5(5):649-657.
[9] WILLIAMS K,MOTIANI K,GIRIDHAR P V,et al. CD44 integrates signaling in normal stem cell,cancer stem cell and (pre) metastatic niches[J].Exp Biol Med (Maywood),2013,238(3):324-338.
[10] ORIAN-ROUSSEAU V. CD44 acts as a signaling platform controlling tumor progression and metastasis[J]. Front Immunol,2015,6(1):154.
[11] THOMPSON S M,CALLSTROM M R,BUTTERS K A,et al. Role for putative hepatocellular carcinoma stem cell subpopulations in biological response to incomplete thermal ablation:in vitro and in vivo pilot study[J]. Cardiovasc Intervent Radiol,2014,37(5):1343-1351.
[12] MALINEE T,WATCHARIN L,ANCHALEE T,et al. CD44 variant-dependent redox status regulation in liver fluke-associated cholangio-carcinoma:A target for cholangiocarcinoma treatment[J]. Cancer Sci,2016,107(7):991-1000.
[13] THANAN R,PAIROJKUL C,PINLAOR S,et al. Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangio-carcinoma patients with poor prognosis[J]. Free Radic Biol Med,2013,65(1):1464-1472.
[14] CHU X,ZHAO P,LV Y,et al. Decreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinoma[J]. Int J Clin Exp Pathol,2015,8(1):328-336.
[15] AHMED H G,ABDUL G S R,ABD E A M,et al. Immunohistochemical expression of cytokeratins and epithelial membrane protein 2 in nasopharyngeal carcinoma and its potential implications[J]. Asian Pac J Cancer Prev,2015,16(2):653-656.
[16] ZHAO Q,YU W L,LU X Y,et al. Combined hepatocellular and cholangiocarcinoma originating from the same clone:a pathomolecular evidence-based study[J]. Chin J Cancer,2016,35(1):82.
[17] WELINDER C,JANSSON B,LINDELL G,et al. Cytokeratin 20 improves the detection of circulating tumor cells in patients with colorectal cancer[J]. Cancer Lett,2015,358(1):43-46.
[18] BONIN S,PRACELLA D,BARBAZZA R,et al.In stage Ⅱ/Ⅲ lymph node-positive breast cancer patients less than 55 years of age,keratin 8 expression in lymph node metastases but not in the primary tumour is an indicator of better survival[J]. Virchows Arch,2015,466(5):571-580.
[19] RADZISHEUSKAYA A,CHIA GLE B,DOS SANTOS RL,et al. A defined Oct4 level governs cell state transitions of pluripotency entry and differentiation into all embryonic lineages[J]. Nat Cell Biol,2013,15(6):579-590.
[20] KAROUBI G,CORTES-DERICKS L,GUGGER M,et al. Atypical expression and distribution of embryonic stem cell marker,OCT4,in human lung adenocarcinoma[J]. J Surg Oncol,2010,102(6):689-698.
[21] HU J,QIU M,JIANG F,et al. MiR-145 regulates cancer stem-like properties and epithelial-to-mesenchymal transition in lung adenocarcinoma-initiating cells[J]. Tumour Biol,2014,35(9):8953-8961.
[22] GAO L,YANG Y,XU H,et al. MiR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4[J]. Tumour Biol,2014,35(8):8309-8318.
[23] WEIKUM E R,TUNTLAND M L,MURPHY M N,et al. A structural investigation into Oct4 regulation by orphan nuclear receptors,germ cell nuclear factor (GCNF) and liver receptor homolog-1(LRH-1)[J]. J Mol Biol,2016,36(16):2981-4992.
[24] 谷化平,黄勇,尚培中. 干细胞转录因子Oct4和CD133蛋白在肝外胆管癌组织中的表达及临床意义[J]. 中国现代普通外科杂志,2014,17(2):112-115.
[25] SHOLL L M,LONG K B,HORNICK J L. Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas[J]. Appl Immuno-histochem Mol Morphol,2010,18(1):55-61.
[26] BOURGUIGNON L Y,WONG G,EARLE C,et al. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal,clonal formation,and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma[J]. J Biol Chem,2012,287(39):32800-32824.
[27] MATSUOKA J,YASHIRO M,SAKURAI K,et al. Role of the stemness factors sox2,oct3/4,and nanog in gastric carcinoma[J]. J Surg Res,2012,174(1):130-135.
[28] SUN Q,LI J,WANG G,et al. Role of the embryonic protein SOX2 in cholangiocarcinoma[J]. Cell Biochem Biophys,2014,70(2):1311-1316.
[29] LIN Y L,HAN Z B,XIONG F Y,et al. Malignant transformation of 293 cells induced by ectopic expression of human Nanog[J]. Mol Cell Biochem,2011,351(1/2):109-116.
[30] SUN C,SUN L,JIANG K,et al. NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transitionthrough NODAL/SMAD3 signaling pathway[J]. Int J Biochem Cell Biol,2013,45(6):1099-1108.
[31] CAVALLONI G,PERALDO-NEIA C,VARAMO C,et al. Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient[J]. Tumour Biol,2016,37(3):4041-4052.
[32] GUO Q,JIAN Z,JIA B,et al. CXCL7 promotes proliferation and invasion of cholangiocarcinoma cells[J]. Oncol Rep,2017,37(2):1114-1122.
[33] SULLIVAN J P,SPINOLA M,DODGE M,et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling[J]. Cancer Res,2010,70(23):9937-9948.
[34] SHUANG Z Y,WU W C,XU J,et al. Transforming growth factor-β1-induced epithelial-mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma[J]. Cancer Lett,2014,354(2):320-328.
[35] LIU D C,YANG Z L,JIANG S,et al. Identification of musashi-1 and ALDH1 as carcinogenesis,progression,and poor-prognosis related biomarkers for gallbladder adenocarcinoma[J]. Cancer Biomark,2011,8(3):113-121.
[36] GUO Z,LI L Q,JIANG J H,et al. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma[J]. World J Gastroenterol,2014,20(8):2098-2106.

胆管癌干细胞标志的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	祝欣萍, 贾迪, 林少辉, 刘晨, 李婧铱, 赵炜明. 新型多金属氧酸盐药物{BiW₈O₃₀}对肝癌SK-HEP-1细胞的抑制作用[J]. 癌变·畸变·突变, 2022, 34(1): 47-52,66.
[2]	问天娇, 李思颖, 郑颖, 崔京霞. 脂质体技术在铂类药物抗肿瘤研究中的应用[J]. 癌变·畸变·突变, 2022, 34(1): 72-74.
[3]	刘宁, 梁兰兰, 李淑芳, 沈祥春, 梁冰. 氧化苦参碱对小鼠肉瘤和肝癌的体内外抗肿瘤作用[J]. 癌变·畸变·突变, 2021, 33(6): 426-429,434.
[4]	王蕊, 王珩, 吴娟, 纪晓坤, 郭晓, 马阳, 杜芸. 全自动DNA图像分析系统在胰腺恶性肿瘤诊断中的价值[J]. 癌变·畸变·突变, 2021, 33(6): 451-454.
[5]	张宗敏. 甲状腺微小癌是否需要手术[J]. 癌变·畸变·突变, 2021, 33(5): 325-326.
[6]	孙惠昕, 张茂祥, 王婉莹, 贾海晗, 宋冰冰. 2013—2017年黑龙江省肿瘤登记地区前列腺癌发病死亡情况及趋势分析[J]. 癌变·畸变·突变, 2021, 33(5): 345-348.
[7]	马亚南, 吴楠, 金焰. 肿瘤微环境与卵巢癌化疗耐药机制的研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 393-395,400.
[8]	李蕊瑞, 张立实, 陈锦瑶. 人群PIG-A基因突变测定的研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 396-400.
[9]	王琛瑶, 梁百慧, 吴锦源, 唐梓涵, 许小文, 尹梓健, 丁雅琼, 方雄钊, 李栢芝, 文姝佚, 程转, 詹涵, 张粤烽, 王泫哲, 何仕龙, 张可洵, 刘雅骐, 周飞, 熊兴东, 白春英, 许丽艳, 李恩民. RAC1对恶性肿瘤的调控作用及其分子机制研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 401-404.
[10]	常晨, 杨荔艳, 蔡洪庆, 苑青, 郝佳洁, 王明荣. 食管鳞癌中SERPINE1 mRNA的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(4): 245-249.
[11]	程书钧. 衰老和恶性肿瘤──防治的思考[J]. 癌变·畸变·突变, 2021, 33(3): 161-162.
[12]	虞欣璐, 于兵, 王辰, 张红霞, 朱海英. 基于四环素诱导型Hnf1β和Foxa3表达载体的小鼠胚胎成纤维细胞转分化为肝干细胞的实验体系研究[J]. 癌变·畸变·突变, 2021, 33(3): 163-171.
[13]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[14]	张竞予, 张雨杭, 于兵, 陈费, 朱海英, 胡以平, 汪超. 血小板生成调节和人工制备的研究进展[J]. 癌变·畸变·突变, 2021, 33(3): 236-240.
[15]	张玉领, 陈培. 环状RNA在食管癌中的研究进展[J]. 癌变·畸变·突变, 2021, 33(3): 241-245.